In conversation with...

Fredrik Schjesvold on OCEAN phase 3

January 31, 2022 The Lancet Haematology
In conversation with...
Fredrik Schjesvold on OCEAN phase 3
Show Notes

Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide.

Read the full article:
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN)